标题
Achieving clinical success with BET inhibitors as anti-cancer agents
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 124, Issue 9, Pages 1478-1490
出版商
Springer Science and Business Media LLC
发表日期
2021-03-15
DOI
10.1038/s41416-021-01321-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
- (2020) Emily J. Faivre et al. NATURE
- Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
- (2020) Shaokun Shu et al. MOLECULAR CELL
- Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation
- (2020) Omer Gilan et al. SCIENCE
- Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors
- (2020) Johanna M. Schafer et al. Science Translational Medicine
- Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
- (2020) V. Moreno et al. ANNALS OF ONCOLOGY
- Bromodomain-selective BET inhibitors are potent antitumor agents against MYC-driven pediatric cancer
- (2020) P. Jake Slavish et al. CANCER RESEARCH
- A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer
- (2020) Rahul R. Aggarwal et al. CLINICAL CANCER RESEARCH
- BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression
- (2020) Thomas E. C. Cummin et al. Blood Advances
- Reprogramming of nucleotide metabolism mediates synergy between epigenetic therapy and MAP Kinase inhibition
- (2020) Tatiana Shorstova et al. MOLECULAR CANCER THERAPEUTICS
- Targeting the IGF1R/PI3K/AKT pathway sensitizes Ewing sarcoma to BET bromodomain inhibitors
- (2019) Sudan N Loganathan et al. MOLECULAR CANCER THERAPEUTICS
- First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
- (2019) Sophie Postel-Vinay et al. EUROPEAN JOURNAL OF CANCER
- SWI/SNF-compromised cancers are susceptible to bromodomain inhibitors
- (2019) Tatiana Shorstova et al. CANCER RESEARCH
- Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail
- (2019) Linlin Lu et al. CELL DEATH AND DIFFERENTIATION
- Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer
- (2019) Sushmita Mustafi et al. EBioMedicine
- The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
- (2019) Aubrey L. Miller et al. EBioMedicine
- Bromodomains: a new target class for drug development
- (2019) Andrea G. Cochran et al. NATURE REVIEWS DRUG DISCOVERY
- Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
- (2019) Laura M. Tsujikawa et al. Clinical Epigenetics
- First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
- (2019) Sarina A. Piha-Paul et al. CLINICAL CANCER RESEARCH
- Acquired Resistance Is Oncogene and Drug Agnostic
- (2019) Robert C. Doebele CANCER CELL
- Bromodomain biology and drug discovery
- (2019) Nilesh Zaware et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo
- (2018) Kun Xu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
- (2018) Chaoyang Sun et al. CANCER CELL
- Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
- (2018) Jeremy Lewin et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-leukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4+ infant ALL
- (2018) Michela Bardini et al. MOLECULAR CANCER THERAPEUTICS
- Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is
- (2018) Sida Liao et al. GENES & DEVELOPMENT
- Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma
- (2018) Jixiang Shi et al. MOLECULAR PHARMACEUTICS
- Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling
- (2018) Amanda Balboni Iniguez et al. CANCER CELL
- NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment
- (2018) Christopher A. French PATHOLOGY INTERNATIONAL
- The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2
- (2017) Torsten Hartwig et al. MOLECULAR CELL
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
- (2017) Pingzhao Zhang et al. NATURE MEDICINE
- Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
- (2017) Hana Janouskova et al. NATURE MEDICINE
- BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
- (2017) Sergey Karakashev et al. Cell Reports
- KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
- (2017) Andrew M. Waters et al. Cold Spring Harbor Perspectives in Medicine
- RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
- (2016) Dean Gilham et al. ATHEROSCLEROSIS
- A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor
- (2016) Junichi Endo et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance
- (2016) Richard Marcotte et al. CELL
- The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
- (2016) J. Shahbazi et al. CLINICAL CANCER RESEARCH
- The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer
- (2016) Yufang Ma et al. CLINICAL CANCER RESEARCH
- OTX015 (MK-8628), a novel BET inhibitor, displaysin vitroandin vivoantitumor effects alone and in combination with conventional therapies in glioblastoma models
- (2016) Caroline Berenguer-Daizé et al. INTERNATIONAL JOURNAL OF CANCER
- Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts
- (2016) Ramiro Vázquez et al. INTERNATIONAL JOURNAL OF CANCER
- The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition
- (2016) Goro Sashida et al. JOURNAL OF EXPERIMENTAL MEDICINE
- HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
- (2016) Xiaoyu Lin et al. MOLECULAR CANCER THERAPEUTICS
- AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
- (2016) G. W. Rhyasen et al. MOLECULAR CANCER THERAPEUTICS
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Design and characterization of bivalent BET inhibitors
- (2016) Minoru Tanaka et al. Nature Chemical Biology
- Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents
- (2016) Olaf Klingbeil et al. Cell Death & Disease
- Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
- (2016) A. Stathis et al. Cancer Discovery
- BET Bromodomain Inhibition Releases the Mediator Complex from Select cis -Regulatory Elements
- (2016) Anand S. Bhagwat et al. Cell Reports
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
- (2015) B. Sun et al. BLOOD
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
- (2015) M. Boi et al. CLINICAL CANCER RESEARCH
- Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
- (2015) A. Henssen et al. CLINICAL CANCER RESEARCH
- Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
- (2015) Elodie Odore et al. CLINICAL PHARMACOKINETICS
- An evaluation of RVX-208 for the treatment of atherosclerosis
- (2015) Dragana Nikolic et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- BRD4 Inhibitor Inhibits Colorectal Cancer Growth and Metastasis
- (2015) Yuan Hu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression
- (2015) R. Lenhart et al. MOLECULAR CANCER THERAPEUTICS
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
- (2015) Pawel K Mazur et al. NATURE MEDICINE
- The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models
- (2015) P L Garcia et al. ONCOGENE
- Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
- (2015) Anastasia Wyce et al. Oncotarget
- Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer
- (2014) Jian Shi et al. CANCER CELL
- Small Molecule Control of Chromatin Remodeling
- (2014) Aidan Finley et al. CHEMISTRY & BIOLOGY
- Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1
- (2014) Marie Jung et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
- (2014) Kevin G. McLure et al. PLoS One
- BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma
- (2014) Joydeep Bhadury et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma
- (2014) Maria Giuseppina Baratta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes
- (2014) M. G. J. Baud et al. SCIENCE
- Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
- (2013) A. Chaidos et al. BLOOD
- Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
- (2013) Bjoern Chapuy et al. CANCER CELL
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
- (2013) T. Shimamura et al. CLINICAL CANCER RESEARCH
- Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
- (2013) Z. Cheng et al. CLINICAL CANCER RESEARCH
- BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
- (2013) P. Bandopadhayay et al. CLINICAL CANCER RESEARCH
- Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation
- (2013) J. Shi et al. GENES & DEVELOPMENT
- BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses
- (2013) A. C. Belkina et al. JOURNAL OF IMMUNOLOGY
- Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains
- (2013) Olivier Mirguet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Regulation of NO Synthesis, Local Inflammation, and Innate Immunity to Pathogens by BET Family Proteins
- (2013) S. Wienerroither et al. MOLECULAR AND CELLULAR BIOLOGY
- MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma
- (2013) A R Grayson et al. ONCOGENE
- BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
- (2013) Anastasia Wyce et al. PLoS One
- RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
- (2013) S. Picaud et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A)
- (2012) Jonathan Seal et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Small-Molecule Inhibition of BRDT for Male Contraception
- (2012) Martin M. Matzuk et al. CELL
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- Down-regulation of NF-κB Transcriptional Activity in HIV-associated Kidney Disease by BRD4 Inhibition
- (2012) Guangtao Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
- (2012) Christopher E Barbieri et al. NATURE GENETICS
- Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
- (2012) W. W. Lockwood et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease
- (2011) Stephen J. Nicholls et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- RVX-208
- (2010) Dana Bailey et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
- (2009) Shuji Ogino et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bromodomain Protein Brd4 Stimulates G1Gene Transcription and Promotes Progression to S Phase
- (2008) Kazuki Mochizuki et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started